Get the Stockscreener App
22.08
0.41%
0.09
Viridian Therapeutics Inc stock is traded at $22.08, with a volume of 1.09M.
It is up +0.41% in the last 24 hours and up +15.72% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
See More
Previous Close:
$21.99
Open:
$22
24h Volume:
1.09M
Relative Volume:
0.53
Market Cap:
$2.50B
Revenue:
$70.92M
Net Income/Loss:
$-342.21M
P/E Ratio:
-5.8655
EPS:
-3.7644
Net Cash Flow:
$-304.30M
1W Performance:
-6.40%
1M Performance:
+15.72%
6M Performance:
-20.86%
1Y Performance:
+19.74%
1-Day Range:
$21.62
$22.23
1-Week Range:
$21.62
$23.83
52-Week Range:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
22.08 | 2.59B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Reiterated | Wedbush | Outperform |
| Dec-03-25 | Initiated | William Blair | Outperform |
| Nov-24-25 | Initiated | Truist | Buy |
| Aug-25-25 | Resumed | Jefferies | Buy |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
Paradigm BioCapital reports 6.1% Viridian (VRDN) stake and 5.3% held by offshore fund - Stock Titan
Kynam Capital group (VRDN) discloses shared power over 6.45M Viridian shares - Stock Titan
T. Rowe Price Associates (VRDN) discloses 5.2% Viridian Therapeutics ownership in 13G - Stock Titan
Deep Track group reports 3.25% Viridian Therapeutics (VRDN) ownership in latest filing - Stock Titan
Viridian Therapeutics, Inc. (1S1) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Trading the Move, Not the Narrative: (VRDN) Edition - news.stocktradersdaily.com
Viridian Therapeutics, Inc. Stock 12‑Month Price Target Cut to $36.07, Implies 58% Upside - TradingView
Analysts Have Just Cut Their Viridian Therapeutics, Inc. (NASDAQ:VRDN) Revenue Estimates By 22% - simplywall.st
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Viridian Therapeutics (VRDN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Evercore Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Just Reported And Analysts Have Been Cutting Their Estimates - Moomoo
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Renaissance Technologies LLC Takes $3.97 Million Position in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Arrowstreet Capital Limited Partnership Has $455,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
VRDN SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
VRDN Maintained by RBC Capital -- Price Target Raised to $36.00 - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Issues Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Viridian Therapeutics to See 'Minimal' Revenue Growth in H2, RBC Capital Markets Says - marketscreener.com
State Street Corporation (NASDAQ: VRDN) discloses 5.5% Viridian Therapeutics ownership - Stock Titan
RBC Adjusts Viridian Therapeutics PT to $36 From $35, Maintains Outperform Speculative Risk Rating - Moomoo
Truist Financial Issues Positive Forecast for Viridian Therapeutics (NASDAQ:VRDN) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $22 to $41 - Moomoo
William Blair Maintains Viridian Therapeutics(VRDN.US) With Buy Rating - Moomoo
Viridian Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Wedbush Adjusts PT on Viridian Therapeutics to $41 From $43, Maintains Outperform Rating - Yahoo Finance
Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q2 Revenue $284,000 - marketscreener.com
Viridian Therapeutics 2Q 2026: Revenue $284K, EPS $(1.05) — 10-Q Summary - TradingView
Viridian Therapeutics Q2 net loss widens as Lumvoa launch lifts costs - TradingView
FDA‑approved TED drug and new notes reshape Viridian Therapeutics (NASDAQ: VRDN) - Stock Titan
Viridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval - TradingView
Press Release: Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results - Moomoo
Viridian Therapeutics (VRDN) Earnings Date and Reports 2026 - MarketBeat
Viridian Therapeutics, Inc. (VRDN): Investor Outlook on a Promising Biotech with 87% Potential Upside - directorstalkinterviews.com
First Trust Advisors LP Grows Stock Holdings in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Stock Rating Lowered by Wall Street Zen - MarketBeat
Principal Financial Group Inc. Lowers Stake in Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics Inc (1S1.DU) stock price, news, quote and history - Yahoo Finance UK
Viridian Therapeutics (VRDN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: A Promising Upside of 83.38% for Biotech Enthusiasts - directorstalkinterviews.com
Eversept Partners LP Sells 1,068,966 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viridian Therapeutics Market Sentiment - Benzinga España
Viridian Therapeutics Inc (VRDN) Institutional Confidence - TradingKey
Viridian Therapeutics Inc (VRDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viridian Therapeutics Inc (VRDN) Income Statement - TradingKey
Viridian Therapeutics Inc (VRDN) Balance Sheet - TradingKey
Viridian Therapeutics Inc (VRDN) Cash Flow - TradingKey
Viridian Therapeutics, Inc. Revenue Breakdown – NASDAQ:VRDN - tradingview.com
Viridian Therapeutics Inc (VRDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):